Mumbai: Pharmaceutical company Venus Remedies said on 11 September it has received regulatory approval for marketing its second research product in Ukraine.
“The company has got success in getting another of its research product, a FDC of Cephalosporin, registered in Ukraine and got regulatory approval for selling in this market,” Venus Remedies said in a filing to the Bombay Stock Exchange.
This combination formulation, developed by Venus Research Wing, is used in the treatment of Febrile Neutropenia, a condition when a patient has fever and suffers a significant reduction in their white blood cells count.
The research product was launched in the domestic market in September 2006 after Phase-III clinical trials and DCGI approval.
Venus Remedies has received success in getting the market authorisation for Ukraine for this innovative formulation from the Ministry of Health (MoH), trade administration on medicines and medicinal devices.
The company has already filed for an international patent for this formulation in Ukraine and an order for bulk supplies of the drug to Ukraine is under execution.
Ukraine being one of the largest markets of CIS, Venus Remedies expects good volume of sales of this specialty injectible which is a remedy for hospital-acquired pneumonia.
The company’s shares were trading at Rs523.50, up 0.34% on the BSE in afternoon trade.